hyaluronan fragment
Phase 2- Indications
- Chronic skin inflammation, Pain, Advanced lung cancer, Chronic wound healing
Company intelligence / Profile preview
Nakhia Impex LLC
Mongoliafacebook.com ↗
- Ownership
- Private
- Employees
- ~110
- Development stage
- Phase 2
01
Overview
Hyaluronan Fragment (HA35) is currently in Phase II clinical development for both Chronic Skin Inflammation and Cancer Pain. The therapeutic candidate is formed by cleaving 1600kDa hyaluronan (HA1600) with hyaluronidase PH20 and is administered through subcutaneous route[2][3].
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small moleculesinjectable solutionsantibiotics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Nakhia Impex LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nakhia Impex LLC.